These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 993634

  • 1. Amikacin therapy for severe gram-negative sepsis: efficacy in infections involving gentamicin-resistant organisms.
    Tally FP, Louie TJ, O'Keefe P, Gorbach SL, Bartlett JG.
    J Infect Dis; 1976 Nov; 134 SUPPL():S428-32. PubMed ID: 993634
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparative effectiveness of combinations of amikacin with penicillin G and amikacin with carbenicillin in gram-negative septicemia: double-blind clinical trial.
    Klastersky J, Hensgens C, Meunier-Carpentier F.
    J Infect Dis; 1976 Nov; 134 SUPPL():S433-40. PubMed ID: 792359
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Amikacin in treatment of infections caused by gram-negative bacteria resistant to gentamicin and other aminoglycosides: clinical and bacteriologic results.
    Daikos GK, Kosmidis JC, Hamilton-Miller JM, Brumfitt W.
    J Infect Dis; 1976 Nov; 134 SUPPL():S286-90. PubMed ID: 993623
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical efficacy of a synergistic combination of cefotaxime and amikacin against multiresistant Pseudomonas and Serratia infections.
    Maslow MJ, Simberkoff MS, Rahal JJ.
    J Antimicrob Chemother; 1985 Aug; 16(2):227-34. PubMed ID: 3934125
    [Abstract] [Full Text] [Related]

  • 11. Amikacin-resistant gram-negative bacilli: correlation of occurrence with amikacin use.
    Levine JF, Maslow MJ, Leibowitz RE, Pollock AA, Hanna BA, Schaefler S, Simberkoff MS, Rahal JJ.
    J Infect Dis; 1985 Feb; 151(2):295-300. PubMed ID: 3918124
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Serum concentrations and inhibitory ratios during amikacin therapy of gram-negative infections.
    Farchione LA, Chudzik GM.
    J Clin Pharmacol; 1978 Feb; 18(8-9):432-8. PubMed ID: 690253
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A review of results of clinical trials with amikacin.
    Gooding PG, Berman E, Lane AZ, Agre K.
    J Infect Dis; 1976 Nov; 134 SUPPL():S441-5. PubMed ID: 792360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.